---
title: "Obefazimod (ABX464) in Ulcerative colitis: Place in treatment, anticipated use, and care setting"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Place in treatment, anticipated use, and care setting. Topics: Summary: anticipated place in therapy, Proposed indication named in the pre-NDA announcement, Population studied in the phase 3 induction trials, Manufacturer positioning as an oral advanced therapy, and 5 further topics. 9 evidence topics quoted from 14 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/place-in-treatment-anticipated-use-and-care-setting"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Place in treatment, anticipated use, and care setting

<a id="heading-2.2.2.2"></a>

## 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

### Summary: anticipated place in therapy

Obefazimod is investigational, and no labeled indication exists. Abivax describes its pre-NDA interaction with the FDA as concerning obefazimod “for the treatment of adults with moderately to severely active ulcerative colitis”. ABTECT-1 and ABTECT-2 enrolled participants with a modified Mayo score of 5 or more who had an inadequate response, loss of response, or intolerance to at least one prior therapy, including corticosteroids, immunosuppressants, biologics, S1P receptor modulators, or JAK inhibitors, with no upper limit; 602 of 1,272 participants (47.3%) had a prior inadequate response to an advanced therapy. Obefazimod is taken orally once daily, whereas the IL-23 p19 inhibitors require intravenous induction (or subcutaneous induction for guselkumab) and subcutaneous maintenance.

Abivax states that it hopes “to position obefazimod as a potential first-line advanced therapy” and that there is no guarantee it would be approved for that use. Abivax estimates that approximately 300,000 moderate-to-severe U.S. patients, out of an estimated 500,000, are on conventional therapy or steroids only, and its research reported that physicians would likely initiate obefazimod in this population “where reluctance to advanced therapies hinder their use.” A Wedbush analyst noted that a boxed warning would limit commercial differentiation against JAK inhibitors.

The AGA 2024 guideline suggests early use of advanced therapies rather than gradual step-up after 5-aminosalicylate failure, and ranks therapies by efficacy separately for advanced therapy-naive and -exposed patients. The ECCO 2026 guideline recommends no treatment or class over another as first-line or subsequent therapy, apart from vedolizumab over adalimumab. The ACG 2025 guideline did not use indirect or post hoc data for its positioning recommendations and states that third-party payers and step therapy requirements “should not come between the patient and their healthcare team”. The BSG 2025 guideline provides no hierarchy. In a cohort of patients newly diagnosed with ulcerative colitis in 2019 to 2023, cumulative 1-year and 5-year use of advanced therapy was 27% and 38%.

Source: [Abivax press release, pre-NDA interaction with the FDA (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-pre-nda-interaction-fda-obefazimod); [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/); [Tremfya prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761061s034lbl.pdf); [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm); [Abivax press release, 2026 corporate outlook (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-provides-2026-corporate-outlook); [Streetwise Reports (2026)](https://www.streetwisereports.com/article/2026/07/01/clinical-stage-biotech-discloses-colitis-retreatment-results-gets-mixed-ratings.html); [Singh et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12162142/); [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617); [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463); [Butler and Segal (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7619135/); [Ahuja et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13456955/); [Omvoh prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761279s005lbl.pdf); [Skyrizi prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761105s053lbl.pdf)

<a id="topic-2.2.2.2-2"></a>

### Proposed indication named in the pre-NDA announcement

> “today announced the successful completion of its positive pre-New Drug Application (NDA) interaction with the U.S. Food and Drug Administration (FDA) for obefazimod for the treatment of adults with moderately to severely active ulcerative colitis”

Source: [Abivax press release, pre-NDA interaction with the FDA (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-announces-positive-pre-nda-interaction-fda-obefazimod)

<a id="topic-2.2.2.2-3"></a>

### Population studied in the phase 3 induction trials

> “The multicenter, randomized, double‐blind, placebo‐controlled ABTECT trials enrolled pts with moderate‐to‐severe UC (defined as modified Mayo score (MMS) ≥ 5, with rectal bleeding sub‐score (RBS) ≥ 1 and centrally read endoscopic score ≥ 2) who had inadequate response, loss of response, or intolerance to at least one prior therapy (with no upper limit), including corticosteroids, immunosuppressants, biologics, S1P receptor modulators and/or JAK inhibitors.”
> “Obefazimod (Obe), an oral, once‐daily (QD), small molecule which enhances expression of microRNA‐124 was studied in patients (pts) with moderately to severely active ulcerative colitis (UC) in Phase 2 studies [1–3].”

Source: [UEG Week (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12605988/)

<a id="topic-2.2.2.2-4"></a>

### Manufacturer positioning as an oral advanced therapy

> “Advance obefazimod through pivotal clinical trials and establish obefazimod as a potential preferred advanced therapy for IBD.”
> “While we hope to position obefazimod as a potential first-line advanced therapy, there is no guarantee that even if approved, it would be approved for first-line advanced therapy. This could limit our potential market opportunity. In addition, we may have to conduct additional clinical trials prior to gaining approval for first-line advanced therapy.”
> “Obefazimod is being developed as a once-daily, oral medication which, combined with its observed tolerability to date, would represent a meaningfully differentiated clinical profile from existing therapies. We believe this may position obefazimod as a potential first-line advanced therapy choice for both prescribers and patients, if approved.”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

<a id="topic-2.2.2.2-5"></a>

### Manufacturer estimate of patients on conventional therapy

> “We currently estimate that approximately 300,000 moderate-to-severe UC patients in the United States, out of an estimated 500,000 patients, are on conventional therapy or steroids only, and a safe, efficacious, oral therapy will have the unique ability to further penetrate this patient segment.”
> “We believe the potential for oral agents to gain significant market share is supported by physician and patient preference for the convenience of oral administration over injectable agents”

Source: [Abivax Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm)

> “The research estimated that roughly 500K patients within the United States are currently on conventional therapies (5ASA’s/corticosteroids), with approximately 60% of these patients being moderate/severe (~300K patients). Physicians indicated they would likely initiate treatment with obefazimod for this population where reluctance to advanced therapies hinder their use.”

Source: [Abivax press release, 2026 corporate outlook (2026)](https://ir.abivax.com/news-releases/news-release-details/abivax-provides-2026-corporate-outlook)

<a id="topic-2.2.2.2-6"></a>

### Analyst view on positioning against Janus kinase inhibitors

> “We also remain mindful of the possibility of a Black Box warning, which would limit commercial differentiation against JAK inhibitors and negatively position obefazimod against emerging classes in IBD, including TL1A inhibitors.”

Source: [Streetwise Reports (2026)](https://www.streetwisereports.com/article/2026/07/01/clinical-stage-biotech-discloses-colitis-retreatment-results-gets-mixed-ratings.html)

<a id="topic-2.2.2.2-7"></a>

### Guideline sequencing: early advanced therapy and absence of a hierarchy

> “In adult outpatients with moderate-severe UC, the AGA suggests early use of advanced therapies with or without immunomodulator therapy, rather than gradual step up after failure of 5-aminosalicylates.”

Source: [Singh et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12162142/)

> “Apart from suggesting the use of vedolizumab rather than adalimumab, no individual treatment or class of treatment can be recommended over another as first-line or subsequent therapy in the treatment of patients with moderate-to-severe ulcerative colitis.”
> “Sequencing therapies in individual patients with moderate-to-severe UC is based on many factors, which among others include patient preference, disease severity, previous treatments, age, efficacy and safety profile of the chosen drug, existing comorbidities, extra-intestinal manifestations, wish to become pregnant, adherence, local availability, and prevailing federal regulations.”

Source: [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617)

> “Therefore, we determined not to use indirect or post hoc data to guide our positioning recommendations.”
> “Patients with UC should have available all medical options as recommended by their doctor and healthcare team. Third-party payers and requirements for step therapy should not come between the patient and their healthcare team in making decisions about treatment for UC.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

> “A summary of recommendations from the 2025 BSG IBD guidelines regarding the use of advanced therapies for induction and maintenance of remission in patients with moderate to severe IBD. Medications are not listed hierarchically.”

Source: [Butler and Segal (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7619135/)

<a id="topic-2.2.2.2-8"></a>

### Current use of advanced therapy in newly diagnosed U.S. adults

> “In a more contemporary cohort of patients diagnosed in 2019–23, the corresponding rate was 27% (95% CI, 24–29) and 38% (95% CI, 34–41), respectively (aHR, 3.43 [95% CI, 2.86–4.13]) (Figure 2C).”

Source: [Ahuja et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13456955/)

<a id="topic-2.2.2.2-9"></a>

### Analyst commentary on cancer risk and a possible boxed warning, June 2026

> “Wedbush analyst David Nierengarten, Ph.D., was less optimistic, citing concerns”
> “on how the FDA will view cancer risk associated with obefazimod.”
> “We also remain mindful of the possibility of a Black Box warning, which would limit commercial differentiation against JAK inhibitors and negatively position obefazimod against emerging classes in IBD, including TL1A inhibitors.”

Source: [Streetwise Reports (2026)](https://www.streetwisereports.com/article/2026/07/01/clinical-stage-biotech-discloses-colitis-retreatment-results-gets-mixed-ratings.html)

Additional sources: [Digestive Disease Week poster, ABTECT integrated safety (2026)](https://www.abivax.com/wp-content/uploads/2026/04/abivax-poster-iss-sands-ddw-2026.pdf)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
